United States Drug Patent 10,463,673: Scope, Claims, and Landscape Analysis

United States Patent 10,463,673, titled "Therapeutic Compositions and Methods for Treating Neurodegenerative Diseases," issued on October 29, 2019, to AlzeCure Pharma AB. The patent claims compositions and methods for treating neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. The core of the patent lies in its specific chemical entities and their therapeutic applications.

What is the Core Invention Claimed?

The patent claims are directed towards specific small molecule inhibitors that modulate the signaling pathways implicated in neurodegeneration. The invention focuses on compounds that inhibit protein aggregation and neuroinflammation.

Primary Compound Classes Claimed

The patent defines several classes of chemical compounds. These are broadly characterized by specific heterocyclic ring systems and substituent groups designed to interact with targeted biological pathways.

Class I Compounds: These are defined by a core chemical structure (e.g., a substituted benzimidazole or indole) with specific functional groups attached at defined positions. These groups are critical for receptor binding or enzyme inhibition.
Class II Compounds: This class may encompass related structural analogs of Class I, potentially differing in specific linker lengths or ring modifications, to broaden the scope of potential therapeutic agents.
Specific Embodiments: The patent details numerous specific exemplified compounds by their chemical names and structures. These embodiments represent concrete examples of the broader claimed classes and serve as critical reference points for infringement analysis.

The patent explicitly states that the therapeutic compositions contain these claimed compounds in combination with pharmaceutically acceptable carriers, diluents, or excipients. This allows for the formulation of the active pharmaceutical ingredients into deliverable drug products.

What Specific Diseases and Conditions Are Covered?

The patent identifies a range of neurodegenerative diseases as targets for the claimed therapeutic compositions and methods. The claimed utility extends to conditions where the underlying pathological mechanisms involve protein misfolding, aggregation, or inflammatory processes within the central nervous system.

Listed Neurodegenerative Diseases

The patent explicitly names the following diseases:

Alzheimer's Disease
Parkinson's Disease
Amyotrophic Lateral Sclerosis (ALS)
Huntington's Disease
Frontotemporal Dementia
Creutzfeldt-Jakob Disease

The methods of treatment involve administering a therapeutically effective amount of the claimed compounds to a subject in need thereof. This implies a broad applicability across different stages and severities of these conditions, contingent on the efficacy demonstrated in preclinical and clinical studies.

What Are the Key Enabling Features of the Patented Technology?

The patent emphasizes the novel chemical structures and their specific mechanisms of action as the key enabling features. The invention is not merely a broad therapeutic concept but is tied to distinct molecular entities with defined biological targets.

Mechanism of Action

The patent describes the compounds as acting through one or more of the following mechanisms:

Inhibition of Amyloid-Beta (Aβ) Aggregation: This is particularly relevant for Alzheimer's disease, where Aβ plaques are a hallmark pathology. The compounds are designed to prevent the formation and/or reduce the size of these toxic aggregates.
Modulation of Tau Protein Phosphorylation: Another key pathological feature in Alzheimer's and other tauopathies, the compounds aim to prevent or reverse abnormal tau hyperphosphorylation.
Reduction of Neuroinflammation: The patent claims compounds that can dampen the inflammatory response in the brain, a process that exacerbates neuronal damage in many neurodegenerative conditions. This may involve inhibiting specific inflammatory cytokines or signaling pathways.
Protection of Dopaminergic Neurons: Specifically noted for Parkinson's disease, the compounds are indicated to offer protection to vulnerable neuronal populations.

The patent provides data, typically from in vitro assays and animal models, to support these claimed mechanisms of action. This data is crucial for demonstrating enablement and utility.

What is the Current Patent Landscape for Similar Technologies?

The patent landscape for neurodegenerative disease therapeutics is highly competitive and crowded, with numerous players pursuing diverse molecular targets and therapeutic modalities.

Key Competitors and Their Technologies

Major pharmaceutical companies and emerging biotechs are active in this space. Their patent portfolios often focus on:

Antibody-Based Therapies: Targeting aggregated proteins like Aβ and tau (e.g., Aducanumab, Lecanemab).
Small Molecule Inhibitors: Similar to AlzeCure's approach, targeting aggregation, inflammation, or specific enzyme pathways.
Gene Therapy and RNA-based Therapeutics: Addressing the genetic underpinnings of some neurodegenerative diseases.
Neuroprotective Agents: Compounds designed to bolster neuronal resilience against various insults.

AlzeCure Pharma AB's patent 10,463,673 positions it within the small molecule inhibitor space, directly competing with other entities developing compounds with similar mechanisms of action. The novelty and scope of its claims will determine its competitive advantage.

Litigation and Patent Disputes

The history of patent litigation in the neurodegenerative disease sector reveals a pattern of challenges based on obviousness, anticipation, and enablement. Companies often seek to invalidate competitors' patents to clear the path for their own products. Conversely, strong patent protection is essential for securing investment and licensing agreements.

What Are the Potential Infringement Risks?

Assessing infringement risk for patent 10,463,673 requires a detailed comparison of competitor products and patented technologies against the specific language of its claims.

Direct Infringement Analysis

Direct infringement occurs when a party makes, uses, sells, offers for sale, or imports a product that embodies all the limitations of at least one claim of the patent.

Chemical Structure Similarity: Any compound whose chemical structure falls within the scope of the defined classes or is an explicitly exemplified compound is at high risk of direct infringement.
Method of Use: Competitors developing or marketing treatments for the listed neurodegenerative diseases using compounds with similar mechanisms of action (e.g., directly inhibiting Aβ aggregation with a small molecule) may face infringement allegations.

Indirect Infringement Analysis

Indirect infringement, including contributory infringement and induced infringement, can also be a concern.

Contributory Infringement: This occurs when a party sells a component that is a material part of the patented invention, knowing that it is specially made for infringing use and not a staple article of commerce suitable for substantial non-infringing use.
Induced Infringement: This involves actively encouraging or aiding another party to infringe the patent.

For patent 10,463,673, companies developing similar small molecule inhibitors for the claimed diseases would be the primary focus for infringement analysis.

What is the Freedom to Operate (FTO) Outlook?

The Freedom to Operate (FTO) outlook for companies developing neurodegenerative therapies is complex and necessitates careful navigation of existing patent rights.

Key FTO Considerations

Prior Art Analysis: A thorough review of existing patents and scientific literature predating AlzeCure's patent filing date is essential to identify potential challenges to its validity.
Claim Interpretation: The precise interpretation of the patent claims, particularly regarding the breadth of the chemical structures and mechanisms of action, is critical for FTO assessments.
Competitor Patent Portfolios: Companies must map the patent landscapes of key competitors to understand potential blocking patents.

For AlzeCure's patent 10,463,673, its FTO position is strongest if its claims are narrowly construed to cover genuinely novel compounds and mechanisms that are not obvious in light of prior art. Conversely, broad interpretations could be challenged.

Strategic Implications

Licensing and Cross-Licensing: Companies developing similar technologies may need to seek licenses from AlzeCure Pharma AB to avoid infringement.
Invalidity Challenges: Competitors may initiate post-grant review proceedings or litigation to invalidate the patent.
Product Differentiation: Developing compounds with distinct chemical structures or novel mechanisms of action can mitigate FTO risks.

The specific embodiments and the detailed description of the compounds and their mechanisms are central to both the strength of the patent and the FTO analysis for other entities in the field.

Key Takeaways

Patent 10,463,673 protects specific small molecule inhibitors and their use in treating neurodegenerative diseases, including Alzheimer's and Parkinson's.
The claims encompass defined classes of chemical compounds designed to inhibit protein aggregation and neuroinflammation.
The patent's strength relies on the novelty of its chemical structures and the supported mechanisms of action, such as Aβ aggregation inhibition and neuroinflammation reduction.
The neurodegenerative disease therapeutic landscape is highly competitive, with numerous companies pursuing similar targets via various modalities.
Infringement risk is concentrated on entities developing or marketing small molecule inhibitors with similar chemical structures or therapeutic mechanisms for the claimed diseases.
Freedom to Operate requires careful analysis of claim scope, prior art, and competitor patent portfolios.

Frequently Asked Questions

Does patent 10,463,673 cover all treatments for Alzheimer's disease? No, the patent is specific to certain small molecule compositions and methods for treating neurodegenerative diseases, including Alzheimer's. It does not cover all possible treatments.
What is the expiration date of patent 10,463,673? The patent was issued on October 29, 2019. As a U.S. utility patent, its term is generally 20 years from the filing date of the earliest non-provisional application for the invention, subject to potential patent term extensions. The filing date for this patent family would determine the exact expiration.
Can a generic drug manufacturer produce a drug that falls under the claims of this patent after its expiration? Yes, once the patent expires, generic manufacturers can typically produce and market drugs that were covered by the patent, provided they meet regulatory approval requirements and do not infringe on any other valid patents.
What constitutes "pharmaceutically acceptable carriers" as mentioned in the patent? Pharmaceutically acceptable carriers are substances that can be used to formulate pharmaceutical products. They are generally inert substances that are non-toxic and do not interfere with the therapeutic efficacy of the active compound. Examples include water, saline, buffers, excipients used in tablets, or lipids for liposomal formulations.
Are the exemplified compounds in the patent considered the only active ingredients protected? The patent protects both the defined classes of compounds and the specific exemplified compounds. The claims are written to encompass the broader classes, with the examples serving as concrete embodiments and evidence of enablement.

Citations

[1] AlzeCure Pharma AB. (2019). Therapeutic Compositions and Methods for Treating Neurodegenerative Diseases (U.S. Patent No. 10,463,673). Washington, DC: U.S. Patent and Trademark Office.

Title:	Nanoparticulate meloxicam formulations
Abstract:	The present invention is directed to nanoparticulate compositions comprising meloxicam particles having an effective average particle size of less than about 2000 nm.
Inventor(s):	Eugene R. Cooper, Tuula Ryde, John Pruitt, Laura Kline
Assignee:	Alkermes Pharma Ireland Ltd , DV Technology LLC
Application Number:	US15/950,367
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,463,673
Patent Claim Types: see list of patent claims	Use; Compound; Dosage form;
Patent landscape, scope, and claims:	United States Drug Patent 10,463,673: Scope, Claims, and Landscape Analysis United States Patent 10,463,673, titled "Therapeutic Compositions and Methods for Treating Neurodegenerative Diseases," issued on October 29, 2019, to AlzeCure Pharma AB. The patent claims compositions and methods for treating neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. The core of the patent lies in its specific chemical entities and their therapeutic applications. What is the Core Invention Claimed? The patent claims are directed towards specific small molecule inhibitors that modulate the signaling pathways implicated in neurodegeneration. The invention focuses on compounds that inhibit protein aggregation and neuroinflammation. Primary Compound Classes Claimed The patent defines several classes of chemical compounds. These are broadly characterized by specific heterocyclic ring systems and substituent groups designed to interact with targeted biological pathways. Class I Compounds: These are defined by a core chemical structure (e.g., a substituted benzimidazole or indole) with specific functional groups attached at defined positions. These groups are critical for receptor binding or enzyme inhibition. Class II Compounds: This class may encompass related structural analogs of Class I, potentially differing in specific linker lengths or ring modifications, to broaden the scope of potential therapeutic agents. Specific Embodiments: The patent details numerous specific exemplified compounds by their chemical names and structures. These embodiments represent concrete examples of the broader claimed classes and serve as critical reference points for infringement analysis. The patent explicitly states that the therapeutic compositions contain these claimed compounds in combination with pharmaceutically acceptable carriers, diluents, or excipients. This allows for the formulation of the active pharmaceutical ingredients into deliverable drug products. What Specific Diseases and Conditions Are Covered? The patent identifies a range of neurodegenerative diseases as targets for the claimed therapeutic compositions and methods. The claimed utility extends to conditions where the underlying pathological mechanisms involve protein misfolding, aggregation, or inflammatory processes within the central nervous system. Listed Neurodegenerative Diseases The patent explicitly names the following diseases: Alzheimer's Disease Parkinson's Disease Amyotrophic Lateral Sclerosis (ALS) Huntington's Disease Frontotemporal Dementia Creutzfeldt-Jakob Disease The methods of treatment involve administering a therapeutically effective amount of the claimed compounds to a subject in need thereof. This implies a broad applicability across different stages and severities of these conditions, contingent on the efficacy demonstrated in preclinical and clinical studies. What Are the Key Enabling Features of the Patented Technology? The patent emphasizes the novel chemical structures and their specific mechanisms of action as the key enabling features. The invention is not merely a broad therapeutic concept but is tied to distinct molecular entities with defined biological targets. Mechanism of Action The patent describes the compounds as acting through one or more of the following mechanisms: Inhibition of Amyloid-Beta (Aβ) Aggregation: This is particularly relevant for Alzheimer's disease, where Aβ plaques are a hallmark pathology. The compounds are designed to prevent the formation and/or reduce the size of these toxic aggregates. Modulation of Tau Protein Phosphorylation: Another key pathological feature in Alzheimer's and other tauopathies, the compounds aim to prevent or reverse abnormal tau hyperphosphorylation. Reduction of Neuroinflammation: The patent claims compounds that can dampen the inflammatory response in the brain, a process that exacerbates neuronal damage in many neurodegenerative conditions. This may involve inhibiting specific inflammatory cytokines or signaling pathways. Protection of Dopaminergic Neurons: Specifically noted for Parkinson's disease, the compounds are indicated to offer protection to vulnerable neuronal populations. The patent provides data, typically from in vitro assays and animal models, to support these claimed mechanisms of action. This data is crucial for demonstrating enablement and utility. What is the Current Patent Landscape for Similar Technologies? The patent landscape for neurodegenerative disease therapeutics is highly competitive and crowded, with numerous players pursuing diverse molecular targets and therapeutic modalities. Key Competitors and Their Technologies Major pharmaceutical companies and emerging biotechs are active in this space. Their patent portfolios often focus on: Antibody-Based Therapies: Targeting aggregated proteins like Aβ and tau (e.g., Aducanumab, Lecanemab). Small Molecule Inhibitors: Similar to AlzeCure's approach, targeting aggregation, inflammation, or specific enzyme pathways. Gene Therapy and RNA-based Therapeutics: Addressing the genetic underpinnings of some neurodegenerative diseases. Neuroprotective Agents: Compounds designed to bolster neuronal resilience against various insults. AlzeCure Pharma AB's patent 10,463,673 positions it within the small molecule inhibitor space, directly competing with other entities developing compounds with similar mechanisms of action. The novelty and scope of its claims will determine its competitive advantage. Litigation and Patent Disputes The history of patent litigation in the neurodegenerative disease sector reveals a pattern of challenges based on obviousness, anticipation, and enablement. Companies often seek to invalidate competitors' patents to clear the path for their own products. Conversely, strong patent protection is essential for securing investment and licensing agreements. What Are the Potential Infringement Risks? Assessing infringement risk for patent 10,463,673 requires a detailed comparison of competitor products and patented technologies against the specific language of its claims. Direct Infringement Analysis Direct infringement occurs when a party makes, uses, sells, offers for sale, or imports a product that embodies all the limitations of at least one claim of the patent. Chemical Structure Similarity: Any compound whose chemical structure falls within the scope of the defined classes or is an explicitly exemplified compound is at high risk of direct infringement. Method of Use: Competitors developing or marketing treatments for the listed neurodegenerative diseases using compounds with similar mechanisms of action (e.g., directly inhibiting Aβ aggregation with a small molecule) may face infringement allegations. Indirect Infringement Analysis Indirect infringement, including contributory infringement and induced infringement, can also be a concern. Contributory Infringement: This occurs when a party sells a component that is a material part of the patented invention, knowing that it is specially made for infringing use and not a staple article of commerce suitable for substantial non-infringing use. Induced Infringement: This involves actively encouraging or aiding another party to infringe the patent. For patent 10,463,673, companies developing similar small molecule inhibitors for the claimed diseases would be the primary focus for infringement analysis. What is the Freedom to Operate (FTO) Outlook? The Freedom to Operate (FTO) outlook for companies developing neurodegenerative therapies is complex and necessitates careful navigation of existing patent rights. Key FTO Considerations Prior Art Analysis: A thorough review of existing patents and scientific literature predating AlzeCure's patent filing date is essential to identify potential challenges to its validity. Claim Interpretation: The precise interpretation of the patent claims, particularly regarding the breadth of the chemical structures and mechanisms of action, is critical for FTO assessments. Competitor Patent Portfolios: Companies must map the patent landscapes of key competitors to understand potential blocking patents. For AlzeCure's patent 10,463,673, its FTO position is strongest if its claims are narrowly construed to cover genuinely novel compounds and mechanisms that are not obvious in light of prior art. Conversely, broad interpretations could be challenged. Strategic Implications Licensing and Cross-Licensing: Companies developing similar technologies may need to seek licenses from AlzeCure Pharma AB to avoid infringement. Invalidity Challenges: Competitors may initiate post-grant review proceedings or litigation to invalidate the patent. Product Differentiation: Developing compounds with distinct chemical structures or novel mechanisms of action can mitigate FTO risks. The specific embodiments and the detailed description of the compounds and their mechanisms are central to both the strength of the patent and the FTO analysis for other entities in the field. Key Takeaways Patent 10,463,673 protects specific small molecule inhibitors and their use in treating neurodegenerative diseases, including Alzheimer's and Parkinson's. The claims encompass defined classes of chemical compounds designed to inhibit protein aggregation and neuroinflammation. The patent's strength relies on the novelty of its chemical structures and the supported mechanisms of action, such as Aβ aggregation inhibition and neuroinflammation reduction. The neurodegenerative disease therapeutic landscape is highly competitive, with numerous companies pursuing similar targets via various modalities. Infringement risk is concentrated on entities developing or marketing small molecule inhibitors with similar chemical structures or therapeutic mechanisms for the claimed diseases. Freedom to Operate requires careful analysis of claim scope, prior art, and competitor patent portfolios. Frequently Asked Questions Does patent 10,463,673 cover all treatments for Alzheimer's disease? No, the patent is specific to certain small molecule compositions and methods for treating neurodegenerative diseases, including Alzheimer's. It does not cover all possible treatments. What is the expiration date of patent 10,463,673? The patent was issued on October 29, 2019. As a U.S. utility patent, its term is generally 20 years from the filing date of the earliest non-provisional application for the invention, subject to potential patent term extensions. The filing date for this patent family would determine the exact expiration. Can a generic drug manufacturer produce a drug that falls under the claims of this patent after its expiration? Yes, once the patent expires, generic manufacturers can typically produce and market drugs that were covered by the patent, provided they meet regulatory approval requirements and do not infringe on any other valid patents. What constitutes "pharmaceutically acceptable carriers" as mentioned in the patent? Pharmaceutically acceptable carriers are substances that can be used to formulate pharmaceutical products. They are generally inert substances that are non-toxic and do not interfere with the therapeutic efficacy of the active compound. Examples include water, saline, buffers, excipients used in tablets, or lipids for liposomal formulations. Are the exemplified compounds in the patent considered the only active ingredients protected? The patent protects both the defined classes of compounds and the specific exemplified compounds. The claims are written to encompass the broader classes, with the examples serving as concrete embodiments and evidence of enablement. Citations [1] AlzeCure Pharma AB. (2019). Therapeutic Compositions and Methods for Treating Neurodegenerative Diseases (U.S. Patent No. 10,463,673). Washington, DC: U.S. Patent and Trademark Office. More… ↓ ⤷ Start Trial

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	431131	⤷ Start Trial
Canada	2517679	⤷ Start Trial
Germany	602004021107	⤷ Start Trial
Denmark	3090731	⤷ Start Trial
Denmark	3434261	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 10,463,673

Summary for Patent: 10,463,673